Ignite Creation Date:
2024-05-06 @ 5:54 PM
Last Modification Date:
2024-10-26 @ 2:38 PM
Study NCT ID:
NCT05478590
Status:
COMPLETED
Last Update Posted:
2023-12-18
First Post:
2022-07-26
Brief Title:
A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
HR POSITIVE HER 2 NEGATIVE ADVANCED BREAST CANCER- TREATMENT PATTERNS IN POLAND - HABER STUDY
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is descriptive and aims to characterize the treatment patterns of advanced breast cancer in Poland in the real-world data setting The main goals are to assess the current treatment patterns of hormone receptor-positive HR Human epidermal growth factor receptor 2 negative HER2- advanced breast cancer and their changes in clinical practice and relate them to patients demographics disease characteristics type of other therapies used in patients as well as disease progression and visceral crisis occurrence
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None